Effect of High Versus Low Fraction of Inspired Oxygen During Alveolar Recruitment

July 11, 2024 updated by: Egymedicalpedia

Comparison of the Effect of High Versus Low Fraction of Inspired Oxygen During Alveolar Recruitment on Absorption Atelectasis in Laparoscopic Bariatric Surgery Patients With Atelectasis

Intraoperative absorption atelectasis is associated with decreased lung compliance, impaired oxygenation, increased pulmonary vascular resistance, and lung injury.

The alveolar recruitment maneuver (RM) with positive-end expiratory pressure (PEEP) has been advocated as efficient for absorption atelectasis treatment.

During general anesthesia, absorption atelectasis reportedly occurs in most patients especially during laparoscopic surgery, the increased abdominal pressure of capnoperitoneum may shift the diaphragm cranially and decrease respiratory compliance

Study Overview

Detailed Description

The incidence of obesity (defined by a body mass index (BMI) > 30 kg/m2) is increasing worldwide. In selected individuals, bariatric surgery may offer means of achieving long-term weight loss, improved health, and healthcare cost reduction. Physiological changes that occur because of obesity and general anesthesia predispose to respiratory complications following bariatric surgery.

Obesity affects many respiratory functions, including, among others, a reduction in functional residual capacity, an increase in airway resistance, and a high level of ventilation-perfusion mismatch. The combination of obesity and postoperative respiratory muscle dysfunction could promote respiratory failure.

Absorption atelectasis occurs in most patients, typically due to absorption of gas, compression of the lung tissue, and impairment of surfactant function. Additionally, during laparoscopic surgery, the increased abdominal pressure of capnoperitoneum may shift the diaphragm cranially and decrease respiratory compliance.

Compression of basal lung regions due to a stiffened diaphragm would accelerate the formation of absorption atelectasis that was already initiated during anesthesia induction.

Such deterioration is associated with pulmonary densities revealed by computed tomography. In addition to physiologic impairment, atelectasis could contribute to perioperative lung injury and PPC.

The RM with PEEP has been advocated as efficient for atelectasis treatment. Reports on the impact of FiO2 during RM on atelectasis development are rare, and have not limited FiO2 to the RM per se.

While RM with high FiO2 can improve oxygenation rapidly, there is a greater possibility of absorption atelectasis occurring.

Diagnostic ultrasonography is the only clinical imaging technology in use that does not depend on electromagnetic radiation. Lung ultrasonography can be considered an attractive complementary diagnostic tool and one of the most promising techniques (Daabis et al., 2014). Therefore, Lung ultrasonography is a safe and cheap tool used during the perioperative period and to detect intraoperative respiratory complications resulting from absorption atelectasis.

The modified Lung Ultrasound Score (LUSS) system involves examination of all intercostal spaces: each hemi-thorax is divided into six regions: 2 anterior, 2 lateral and 2 posterior with four longitudinal lines and one axial line [figure 1 (B, C)]. Each region score shows sufficient sensitivity to detect loss of aeration during laparoscopic surgery. The degree of de-aeration rated from 0 to 3 (zero for no atelectasis and 3 for complete atelectasis ) defining substantial atelectasis as a score of 2 or 3 assigned to any region

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Abbasia
      • Cairo, Abbasia, Egypt
        • Ain Shams University Hospitals

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients aged between 18 - 60 years old.
  • Both genders.
  • Preoperative Physical Status: ASA II, III Patients.
  • BMI above 40 Kg/m2.
  • Patients undergoing laparoscopic bariatric surgeries: laparoscopic mini gastric bypass, Roux-en-Y gastric bypass and revision bariatric surgery (redo bariatric surgery) with the presence of atelectasis confirmed radiologically by Chest X-ray (CXR) and CT Chest

Exclusion Criteria:

  • Refusal of the intervention or participation in the study.
  • Patient under age of 18 years old or above 60 years old.
  • Preoperative Physical Status: ASA I, IV.
  • Psychiatric illness.
  • Known cases of chronic pulmonary disease e.g. COPD and bronchial asthma.
  • Known cases of cardiac diseases.
  • Previous lung surgery.
  • Lactation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: High Fraction of Inspired Oxygen(Group A)
About 40 patients received FiO2 1.0 during recruitment maneuvers
to compare the effect of high oxygen fraction (FiO2 1.0) vs. low oxygen fraction (FiO2 0.4) on clinical outcome on intraoperative and postoperative atelectasis and PPC. We will asses the impact of FiO2, especially during RM, on atelectasis development, using modified LUSS in obese patients with atelectasis undergoing laparoscopic bariatric surgery.
Active Comparator: Low Fraction of Inspired Oxygen(Group B)
About 40 patients received FiO2 0.4 during recruitment maneuvers
to compare the effect of high oxygen fraction (FiO2 1.0) vs. low oxygen fraction (FiO2 0.4) on clinical outcome on intraoperative and postoperative atelectasis and PPC. We will asses the impact of FiO2, especially during RM, on atelectasis development, using modified LUSS in obese patients with atelectasis undergoing laparoscopic bariatric surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Modified Lung Ultrasound Score (LUSS)
Time Frame: from 0 hours to 6 hours after the procedure
1. Modified LUSS at surgery completion compared to baseline preoperative modified LUSS, reflecting any aeration loss during general anesthesia.
from 0 hours to 6 hours after the procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Study Chair: Madiha Metwaly Zidan, Professor, Department of Anesthesia and I.C.U. faculty of Medicine,Ain Shams university, Egypt
  • Study Director: Ahmed Ali Fawaz, Professor, Department of Anesthesia and I.C.U. faculty of Medicine,Ain Shams university, Egypt

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 7, 2023

Primary Completion (Actual)

July 7, 2024

Study Completion (Actual)

July 10, 2024

Study Registration Dates

First Submitted

July 2, 2024

First Submitted That Met QC Criteria

July 2, 2024

First Posted (Actual)

July 10, 2024

Study Record Updates

Last Update Posted (Actual)

July 15, 2024

Last Update Submitted That Met QC Criteria

July 11, 2024

Last Verified

February 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • Abdallah Adel Saber

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe